Cargando…
A Phase I clinical trial of carbon ion radiotherapy for Stage I breast cancer: clinical and pathological evaluation
Even with its high RBE and >20 years history, there had been no breast cancer clinical trial using carbon-ion radiotherapy. We started a Phase I trial of carbon ion radiotherapy for Stage I breast cancer in 2013. This article describes the clinical and pathological evaluation of this study. Patie...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6530622/ https://www.ncbi.nlm.nih.gov/pubmed/30805611 http://dx.doi.org/10.1093/jrr/rry113 |
_version_ | 1783420691049086976 |
---|---|
author | Karasawa, Kumiko Omatsu, Tokuhiki Arakawa, Atsushi Yamamoto, Naohito Ishikawa, Takashi Saito, Mitsue Fukuda, Shigekazu Kamada, Tadashi |
author_facet | Karasawa, Kumiko Omatsu, Tokuhiki Arakawa, Atsushi Yamamoto, Naohito Ishikawa, Takashi Saito, Mitsue Fukuda, Shigekazu Kamada, Tadashi |
author_sort | Karasawa, Kumiko |
collection | PubMed |
description | Even with its high RBE and >20 years history, there had been no breast cancer clinical trial using carbon-ion radiotherapy. We started a Phase I trial of carbon ion radiotherapy for Stage I breast cancer in 2013. This article describes the clinical and pathological evaluation of this study. Patients with low-risk Stage I breast cancer were eligible. A dose escalation study was designed, with dose levels of 48.0, 52.8 or 60.0 Gy relative biological effectiveness (RBE) administered in four fractions within 1 week. Three months after radiotherapy, the patients underwent tumor excision for pathological evaluation. Between April 2013 and December 2014, three cases receiving 48 Gy (RBE), three cases receiving 52.8 Gy (RBE) and one case receiving 60 Gy (RBE) underwent this protocol. No adverse effects were observed except for Grade 1 acute skin reaction in four cases. Pathological evaluation revealed that all four cases with doses of 52.8 Gy (RBE) and 60.0 Gy (RBE) achieved Grade 2b or more, but only two cases reached Grade 3. At the end of 2017, all cases were alive without recurrence or late had not caused any late adverse reaction. Carbon ion radiotherapy for Stage I breast cancer seems to be safe, and we found that it did not reach enough treatment effect 3 months after the treatment. |
format | Online Article Text |
id | pubmed-6530622 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-65306222019-05-28 A Phase I clinical trial of carbon ion radiotherapy for Stage I breast cancer: clinical and pathological evaluation Karasawa, Kumiko Omatsu, Tokuhiki Arakawa, Atsushi Yamamoto, Naohito Ishikawa, Takashi Saito, Mitsue Fukuda, Shigekazu Kamada, Tadashi J Radiat Res Regular Paper Even with its high RBE and >20 years history, there had been no breast cancer clinical trial using carbon-ion radiotherapy. We started a Phase I trial of carbon ion radiotherapy for Stage I breast cancer in 2013. This article describes the clinical and pathological evaluation of this study. Patients with low-risk Stage I breast cancer were eligible. A dose escalation study was designed, with dose levels of 48.0, 52.8 or 60.0 Gy relative biological effectiveness (RBE) administered in four fractions within 1 week. Three months after radiotherapy, the patients underwent tumor excision for pathological evaluation. Between April 2013 and December 2014, three cases receiving 48 Gy (RBE), three cases receiving 52.8 Gy (RBE) and one case receiving 60 Gy (RBE) underwent this protocol. No adverse effects were observed except for Grade 1 acute skin reaction in four cases. Pathological evaluation revealed that all four cases with doses of 52.8 Gy (RBE) and 60.0 Gy (RBE) achieved Grade 2b or more, but only two cases reached Grade 3. At the end of 2017, all cases were alive without recurrence or late had not caused any late adverse reaction. Carbon ion radiotherapy for Stage I breast cancer seems to be safe, and we found that it did not reach enough treatment effect 3 months after the treatment. Oxford University Press 2019-05 2019-02-26 /pmc/articles/PMC6530622/ /pubmed/30805611 http://dx.doi.org/10.1093/jrr/rry113 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of The Japan Radiation Research Society and Japanese Society for Radiation Oncology. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Regular Paper Karasawa, Kumiko Omatsu, Tokuhiki Arakawa, Atsushi Yamamoto, Naohito Ishikawa, Takashi Saito, Mitsue Fukuda, Shigekazu Kamada, Tadashi A Phase I clinical trial of carbon ion radiotherapy for Stage I breast cancer: clinical and pathological evaluation |
title | A Phase I clinical trial of carbon ion radiotherapy for Stage I breast cancer: clinical and pathological evaluation |
title_full | A Phase I clinical trial of carbon ion radiotherapy for Stage I breast cancer: clinical and pathological evaluation |
title_fullStr | A Phase I clinical trial of carbon ion radiotherapy for Stage I breast cancer: clinical and pathological evaluation |
title_full_unstemmed | A Phase I clinical trial of carbon ion radiotherapy for Stage I breast cancer: clinical and pathological evaluation |
title_short | A Phase I clinical trial of carbon ion radiotherapy for Stage I breast cancer: clinical and pathological evaluation |
title_sort | phase i clinical trial of carbon ion radiotherapy for stage i breast cancer: clinical and pathological evaluation |
topic | Regular Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6530622/ https://www.ncbi.nlm.nih.gov/pubmed/30805611 http://dx.doi.org/10.1093/jrr/rry113 |
work_keys_str_mv | AT karasawakumiko aphaseiclinicaltrialofcarbonionradiotherapyforstageibreastcancerclinicalandpathologicalevaluation AT omatsutokuhiki aphaseiclinicaltrialofcarbonionradiotherapyforstageibreastcancerclinicalandpathologicalevaluation AT arakawaatsushi aphaseiclinicaltrialofcarbonionradiotherapyforstageibreastcancerclinicalandpathologicalevaluation AT yamamotonaohito aphaseiclinicaltrialofcarbonionradiotherapyforstageibreastcancerclinicalandpathologicalevaluation AT ishikawatakashi aphaseiclinicaltrialofcarbonionradiotherapyforstageibreastcancerclinicalandpathologicalevaluation AT saitomitsue aphaseiclinicaltrialofcarbonionradiotherapyforstageibreastcancerclinicalandpathologicalevaluation AT fukudashigekazu aphaseiclinicaltrialofcarbonionradiotherapyforstageibreastcancerclinicalandpathologicalevaluation AT kamadatadashi aphaseiclinicaltrialofcarbonionradiotherapyforstageibreastcancerclinicalandpathologicalevaluation AT aphaseiclinicaltrialofcarbonionradiotherapyforstageibreastcancerclinicalandpathologicalevaluation AT karasawakumiko phaseiclinicaltrialofcarbonionradiotherapyforstageibreastcancerclinicalandpathologicalevaluation AT omatsutokuhiki phaseiclinicaltrialofcarbonionradiotherapyforstageibreastcancerclinicalandpathologicalevaluation AT arakawaatsushi phaseiclinicaltrialofcarbonionradiotherapyforstageibreastcancerclinicalandpathologicalevaluation AT yamamotonaohito phaseiclinicaltrialofcarbonionradiotherapyforstageibreastcancerclinicalandpathologicalevaluation AT ishikawatakashi phaseiclinicaltrialofcarbonionradiotherapyforstageibreastcancerclinicalandpathologicalevaluation AT saitomitsue phaseiclinicaltrialofcarbonionradiotherapyforstageibreastcancerclinicalandpathologicalevaluation AT fukudashigekazu phaseiclinicaltrialofcarbonionradiotherapyforstageibreastcancerclinicalandpathologicalevaluation AT kamadatadashi phaseiclinicaltrialofcarbonionradiotherapyforstageibreastcancerclinicalandpathologicalevaluation AT phaseiclinicaltrialofcarbonionradiotherapyforstageibreastcancerclinicalandpathologicalevaluation |